Cognition Therapeutics - CGTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.20
  • Forecasted Upside: 331.60%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$1.90
▼ -0.0001 (-0.01%)

This chart shows the closing price for CGTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cognition Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CGTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CGTX

Analyst Price Target is $8.20
▲ +331.60% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Cognition Therapeutics in the last 3 months. The average price target is $8.20, with a high forecast of $11.00 and a low forecast of $5.00. The average price target represents a 331.60% upside from the last price of $1.90.

This chart shows the closing price for CGTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Cognition Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/6/2024Chardan CapitalInitiated CoverageBuy$11.00Low
5/29/2024HC WainwrightInitiated CoverageBuy$10.00Low
3/28/2024B. RileyReiterated RatingBuy ➝ Buy$5.00N/A
3/27/2024OppenheimerReiterated RatingOutperform ➝ Outperform$9.00Low
8/14/2023LADENBURG THALM/SH SHLower TargetBuy ➝ Buy$10.00 ➝ $6.00Low
11/15/2022OppenheimerLower Target$18.00 ➝ $9.00Low
9/29/2022Cantor FitzgeraldReiterated RatingOverweightLow
4/22/2022LADENBURG THALM/SH SHInitiated CoverageBuy$10.00Low
1/24/2022B. RileyLower Target$27.00 ➝ $20.00High
11/30/2021B. RileyReiterated RatingBuyHigh
11/3/2021OppenheimerInitiated CoverageOutperform$22.00High
11/3/2021B. RileyInitiated CoverageBuy$27.00High
(Data available from 6/24/2019 forward)

News Sentiment Rating

1.06 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/26/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2024
  • 1 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2024
  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/25/2024
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2024

Current Sentiment

  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Cognition Therapeutics logo
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.
Read More

Today's Range

Now: $1.90
Low: $1.88
High: $1.95

50 Day Range

MA: $2.03
Low: $1.83
High: $2.62

52 Week Range

Now: $1.90
Low: $0.90
High: $2.98

Volume

8,082 shs

Average Volume

180,495 shs

Market Capitalization

$76.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53

Frequently Asked Questions

What sell-side analysts currently cover shares of Cognition Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Cognition Therapeutics in the last year: B. Riley, Chardan Capital, HC Wainwright, LADENBURG THALM/SH SH, and Oppenheimer Holdings Inc..
View the latest analyst ratings for CGTX.

What is the current price target for Cognition Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Cognition Therapeutics in the last year. Their average twelve-month price target is $8.20, suggesting a possible upside of 331.6%. Chardan Capital has the highest price target set, predicting CGTX will reach $11.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $5.00 for Cognition Therapeutics in the next year.
View the latest price targets for CGTX.

What is the current consensus analyst rating for Cognition Therapeutics?

Cognition Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CGTX will outperform the market and that investors should add to their positions of Cognition Therapeutics.
View the latest ratings for CGTX.

What other companies compete with Cognition Therapeutics?

How do I contact Cognition Therapeutics' investor relations team?

The company's listed phone number is 412-481-2210 and its investor relations email address is [email protected]. The official website for Cognition Therapeutics is www.cogrx.com. Learn More about contacing Cognition Therapeutics investor relations.